Cargando…

Long-term safety of etanercept in psoriasis: Retrospective study focused on infections

OBJECTIVE: Retrospective study to evaluate the incidence of infectious adverse events in patients with psoriasis treated with etanercept. METHODS: Patients with psoriasis or psoriatic arthritis who were treated with etanercept (50 mg, administered weekly via subcutaneous injection) for ≥48 weeks wer...

Descripción completa

Detalles Bibliográficos
Autores principales:	Orsini, Diego, Narcisi, Alessandra, Arcese, Annalisa, Costanzo, Antonio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2016
Materias:	Immuno-Mediated Diseases And Comorbities
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5536529/ https://www.ncbi.nlm.nih.gov/pubmed/27683141 http://dx.doi.org/10.1177/0300060515593252

Ejemplares similares

Suicide risk and psychiatric comorbidity in patients with psoriasis
por: Pompili, Maurizio, et al.
Publicado: (2016)

Treatment of psoriasis with etanercept in immunocompromised patients: Two case reports
por: De Simone, Clara, et al.
Publicado: (2016)

Long-term treatment with adalimumab in psoriatic arthritis: serum adalimumab concentration, immunogenicity and the link with clinical response
por: Chimenti, Maria Sole, et al.
Publicado: (2016)

Influence of body mass index and weight on etanercept efficacy in patients with psoriasis: A retrospective study
por: Giunta, Alessandro, et al.
Publicado: (2016)

Cardiovascular risk evaluation through heart rate variability analysis in psoriatic patients before and after 24 weeks of etanercept therapy: Prospective study
por: Potenza, Concetta, et al.
Publicado: (2016)

Beneficial effects of long-term treatment with bosentan on the development of pulmonary arterial hypertension in patients with systemic sclerosis
por: Murdaca, Giuseppe, et al.
Publicado: (2016)

Post-translational modifications in rheumatoid arthritis and atherosclerosis: Focus on citrullination and carbamylation
por: Spinelli, Francesca Romana, et al.
Publicado: (2016)

How the immune system responds to therapeutic biological agents
por: Vultaggio, Alessandra, et al.
Publicado: (2016)

Asymmetric dimethylarginine and arterial stiffness in patients with rheumatoid arthritis: A case–control study
por: Erre, Gian Luca, et al.
Publicado: (2016)

Serological markers associated with disease activity in patients with rheumatoid arthritis treated with rituximab
por: Conigliaro, Paola, et al.
Publicado: (2016)

Safety of Immune Checkpoint Inhibitors in Patients With Advanced Chronic Kidney Disease: A Retrospective Cohort Study
por: Tiu, Bruce C, et al.
Publicado: (2023)

Long-term safety and efficacy of adalimumab in psoriasis: a multicentric study focused on infections (connecting study)
por: Narcisi, Alessandra, et al.
Publicado: (2020)

The effect of etanercept on vascular endothelial growth factor production by cutaneous mesenchymal stem cells from patients with psoriasis
por: Campanati, Anna, et al.
Publicado: (2016)

Impact of Interventions Targeting Unhealthy Alcohol Use in Kenya on HIV Transmission and AIDS-Related Deaths
por: Braithwaite, R Scott, et al.
Publicado: (2014)

Safety of Immune Checkpoint Inhibitors in Patients with Cancer and Hepatitis C Virus Infection
por: Alkrekshi, Akram, et al.
Publicado: (2021)

Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and Viral Hepatitis: The MD Anderson Cancer Center Experience
por: Nardo, Mirella, et al.
Publicado: (2023)

Safety and Clinical Activity of SHR7390 Monotherapy or Combined With Camrelizumab for Advanced Solid Tumor: Results From Two Phase I Trials
por: Wei, Xiao-Li, et al.
Publicado: (2022)

S100A8/A9 in psoriatic plaques from patients with psoriatic arthritis
por: Chimenti, Maria Sole, et al.
Publicado: (2016)

Ongoing Phase I Studies of Immune Checkpoint Inhibitors in China
por: Fang, Wenfeng, et al.
Publicado: (2019)

Immune‐Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders with Advanced Non‐Small Cell Lung Cancer
por: Akamatsu, Hiroaki, et al.
Publicado: (2019)

Combined Effect of Sarcopenia and Systemic Inflammation on Survival in Patients with Advanced Stage Cancer Treated with Immunotherapy
por: Bilen, Mehmet Asim, et al.
Publicado: (2019)

PD‐L1 Expression on Circulating Tumor Cells May Be Predictive of Response to Pembrolizumab in Advanced Melanoma: Results from a Pilot Study
por: Khattak, Muhammad A., et al.
Publicado: (2019)

Systematic Review of PD‐1/PD‐L1 Inhibitors in Oncology: From Personalized Medicine to Public Health
por: Chang, Elaine, et al.
Publicado: (2021)

The Inconsistent and Inadequate Reporting Of Immune‐Related Adverse Events in PD‐1/PD‐L1 Inhibitors: A Systematic Review of Randomized Controlled Clinical Trials
por: Xie, Tong, et al.
Publicado: (2021)

Humoral Immune Response of SARS‐CoV‐2–Infected Patients with Cancer: Influencing Factors and Mechanisms
por: Esperança‐Martins, Miguel, et al.
Publicado: (2021)

Analysis of Real‐World Data to Investigate the Impact of Race and Ethnicity on Response to Programmed Cell Death‐1 and Programmed Cell Death‐Ligand 1 Inhibitors in Advanced Non‐Small Cell Lung Cancers
por: Ayers, Kristin L., et al.
Publicado: (2021)

Patient Blood Type Is Associated With Response to Immune Checkpoint Blockade in Metastatic Cancer
por: Chen, Ruifeng, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors: The Unexplored Landscape of Geriatric Oncology
por: Choucair, Khalil, et al.
Publicado: (2022)

Phase II Trial of MEDI0457 and Durvalumab for Patients With Recurrent/Metastatic Human Papillomavirus-Associated Cancers
por: Morris, Van K, et al.
Publicado: (2023)

Evaluating Survival After Hospitalization Due to Immune-Related Adverse Events From Checkpoint Inhibitors
por: Silverstein, Jordyn, et al.
Publicado: (2023)

Identification of Immune Subtypes and Candidate mRNA Vaccine Antigens in Small Cell Lung Cancer
por: Wei, Yuanfeng, et al.
Publicado: (2023)

Characteristics of Immune Checkpoint Inhibitor-Associated Gastritis: Report from a Major Tertiary Care Center
por: Farha, Natalie, et al.
Publicado: (2023)

Association Between Rheumatic Autoantibodies and Immune-Related Adverse Events
por: Mathias, Kristen, et al.
Publicado: (2023)

Long term efficacy and safety of etanercept in the treatment of psoriasis and psoriatic arthritis
por: Kivelevitch, Dario, et al.
Publicado: (2014)

The safety of etanercept for the treatment of plaque psoriasis
por: Papp, Kim A
Publicado: (2007)

Salivary interleukin-1β: Oral inflammatory biomarker in patients with psoriasis
por: Ganzetti, Giulia, et al.
Publicado: (2016)

Safety of Biologic Therapies in Patients with Moderate-to-Severe Plaque Psoriasis and Concomitant Viral Hepatitis: A Monocentric Retrospective Study
por: Gargiulo, Luigi, et al.
Publicado: (2022)

Etanercept in the treatment of plaque psoriasis
por: Nguyen, Thao U, et al.
Publicado: (2009)

Utility of fluorescence imitating brightfield imaging microscopy for the diagnosis of feline chronic enteropathy
por: Au Yeung, Sarah, et al.
Publicado: (2022)

Long-Term Cost-Effectiveness Analysis of Etanercept and Adalimumab for Plaque Psoriasis not Associated with Arthritis
por: Ruano, Juan, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_npq7g4aibnso37mhpugsqtkbqq